BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• Press Releases

  Hengdian Group’s Apeloa Pharmaceutical uses Flow Chemistry for sustainable manufacturing

  August 27, 2025

   · 

  3 min read
• Press Releases

  Large Independent Randomized Controlled Trial Validates MolecuLight’s Transformative Impact on Wound Debridement, Showing Improved Outcomes and Lower Costs

  August 27, 2025

   · 

  4 min read
• Press Releases

  Innovent Announces 2025 Interim Results and Business Updates

  August 27, 2025

   · 

  10 min read
• Press Releases

  European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

  August 27, 2025

   · 

  9 min read
• Press Releases

  Compass Pathways to Participate in Four Investor Conferences in September 2025

  August 27, 2025

   · 

  1 min read
• 

  Layoffs

  Pfizer Cuts 100 From Former Seagen HQ Amid ‘Digital Enablement and Automation’ Push

  The layoffs will affect employees at Pfizer’s Bothell, Washington site, which previously served as the headquarters for Seagen before being acquired by the pharma for $43 billion.

  August 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win

  Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.  

  August 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  TrialAssure’s Zach Weingarden Joins Other Pharmaceutical Industry Leaders to Present on the Future of AI in Drug Development at RAPS Convergence 2025

  August 27, 2025

   · 

  1 min read
• 

  Neuroscience

  Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier

  Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.

  August 27, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Amylyx Axes Drug Program for Rare Neurodegenerative Disorder

  AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year—was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.

  August 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac